Senti Biosciences CFO Yvonne Li departs; transition consultant through March 31

Senti Biosciences, Inc.

Yvonne Li's consulting agreement as Interim CFO expired Jan 31, 2025; she ceased as principal financial and accounting officer.
Entered new consulting agreement on Feb 5, 2025 for transition support until March 31, 2025.
No permanent CFO appointment announced; Li will cooperate with executive management on orderly handover.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Yvonne Li

Interim Chief Financial Officer

SNTI · Senti Biosciences, Inc.

Effective: 2025-01-31
Filed: February 6, 2025, 6:59 PM ET

On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yvonne Li departed as Interim Chief Financial Officer at Senti Biosciences, Inc..

Action: ceased
Role: Interim Chief Financial Officer

Exact text from the filing

On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.

View on SEC.gov

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-004293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.